Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
absci
Overview
Absci is a leading biopharmaceutical company transforming drug discovery by integrating its proprietary, data-driven, AI-powered platform with synthetic biology. Focusing on de novo design of biologics and complex molecules, Absci aims to overcome limitations in traditional drug development, enabling faster and more efficient creation of novel therapeutics with optimized properties for a wide range of diseases. The company operates in the highly competitive biotechnology sector, specifically targeting protein-based therapeutics, and differentiates itself through its unique 'Integrated Drug Creation Platform', which combines AI with in vitro and in vivo testing to accelerate the identification and validation of drug candidates.
absci's headcount breakdown by department
| Department | HeadCount |
|---|---|
Administrative | 1 |
Consulting | 3 |
Service | 0 |
Design | 0 |
Education | 0 |
Absci's departmental structure demonstrates a clear prioritization of research, development, and technological innovation. The substantial allocation of personnel to 'Research' (53) and 'Technical' (28) roles underscores their commitment to advancing their AI-powered drug creation platform and discovering novel biologics. A significant contingent in the 'Other Department' category (35) likely supports crucial functions like platform engineering, data management, and specialized laboratory operations, all vital to their technology-centric approach. The smaller teams dedicated to 'Finance' (4), 'HR' (4), 'Marketing' (2), and 'Sales' (5) suggest that while commercial viability is a consideration, the company's primary focus remains firmly on scientific advancement and platform development, a common strategy for early-stage, research-intensive biotech companies. The limited investment in 'Consulting' (3), 'Product' (2), and 'Project Management' (2) further reinforces the internally-driven nature of their innovation, highlighting a strategy of retaining core expertise in-house to maintain a competitive edge in the rapidly evolving field of AI-driven drug discovery. This structure indicates a tech-heavy and research-focused business model, emphasizing the development of a differentiated technology platform over immediate commercialization.
absci's employees by locations
Employee Count by Country
Total: 159 employees
Absci exhibits a predominantly US-centric operational model, with a significant concentration of its workforce in the United States (141 employees). This likely reflects their origin, access to funding, proximity to key research institutions, and the availability of a skilled workforce in biotechnology and AI. However, the presence of personnel in Serbia (7) and Switzerland (5) suggests a strategic approach to accessing specific talent pools, possibly for data science, bioinformatics, or specialized engineering skills at potentially lower costs compared to the US. The smaller presence in Western European countries such as the Netherlands (1), Germany (1), and the United Kingdom (2) may indicate partnerships with academic institutions, access to specialized expertise, or strategic positioning for future market entry and clinical trial sites. The single employee in Côte d'Ivoire is an outlier and warrants further investigation, potentially representing a unique partnership or research opportunity related to a specific disease area. Overall, Absci's geographic distribution reflects a primarily domestic focus with strategic international expansion to leverage specific skills and research opportunities, aligning with a business model reliant on innovation and access to specialized talent.
Want to stay ahead of absci's org changes?
Get alerts when hiring spikes or teams shift focus
Track changes vs. competitors
Spot warm GTM signals early